New LSD-Based Therapy Shows Promise for Depression

Millions of people living with major depression may soon have access to a treatment that works better than anything currently available.

Definium Therapeutics announced Monday that their oral LSD-based medication, called DT120, met every goal in a Phase 3 clinical trial for major depressive disorder. The company's stock jumped more than 50% as investors recognized the breakthrough.

The numbers tell an impressive story. Patients taking DT120 showed an 8.1-point improvement on the standard depression scale compared to those taking a placebo over six weeks. That improvement lasted, with patients still showing a 7.3-point reduction at 12 weeks.

To put that in perspective, DT120 outperformed every depression medication currently on the market, according to financial analysts reviewing the data. They called the results "profound."

What makes this especially exciting is how long the effects last. Unlike Johnson & Johnson's ketamine spray Spravato, which requires frequent dosing, DT120's lasting impact suggests patients might need treatment far less often. That could mean fewer doctor visits and better quality of life.

CEO Rob Barrow called DT120 a "potential best-in-class treatment for mental health disorders." The company is now moving toward FDA submission and already testing the medication for generalized anxiety disorder and post-traumatic stress disorder.

The Ripple Effect

This breakthrough arrives at a pivotal moment for mental health treatment. The psychedelics field has gained serious momentum, with the FDA making these therapies a regulatory priority. President Trump signed an executive order last year specifically to advance psychedelic mental health treatments.

Definium isn't alone in this space. Companies like Compass Pathways are developing psilocybin-based therapies, creating what one analyst called "a very big year for psychedelics." After decades of research being blocked, scientists can finally explore how these substances might help people suffering from conditions that traditional medications haven't fully addressed.

The trial, called Emerge, showed no new safety concerns. For the estimated 21 million American adults who experience major depressive disorder each year, many of whom don't respond well to current treatments, this could represent a fundamentally different path forward.

Definium, formerly known as MindMed, changed its name in January and continues expanding its research into other mental health applications, including a formulation of MDMA for autism spectrum disorder.

The company expects to submit their findings to the FDA soon, bringing these decades of scientific research one step closer to helping people who desperately need new options.